Skip to main content
Ruben de Kanter on Muck Rack

Ruben de Kanter

As seen in: Nature, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruben

Contact Ruben, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers - Nature

|
By Ruben de Kanter, Clemens Scheufler, Grainne Kerr, Joseph Schoepfer, Markus Wartmann, Henrik Möbitz, Hans Voshol
| Nature Verified
Abstract The Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens1,2,3,4,5,6. Despite advances in treatment with immune checkpoint inhibitors7,8,9,10, there is an unmet need in the treatment of MSI cancers11,12,13,14.
Open in Who Shared Issue with article?

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG

|
By William Brian, Larry M Tremaine, Million Arefayene, Ruben de Kanter, Raymond Evers
| Future Medicine Verified
Genetic variants of drug metabolism enzymes and transporters can result in high pharmacokinetic and pharmacodynamic variability, unwanted characteristics of efficacious and safe drugs. Ideally, the contributions of these enzymes and transporters to drug disposition can be predicted from in vitro experiments and in silico modeling in discovery or early development, and then be utilized during clinical development.
Open in Who Shared Issue with article?
See all 2 articles